Highlights of the SWAN Thyroid-CVD Analysis
The Study of Women’s Health Across the Nation (SWAN) provides critical long-term data regarding the safety profile of levothyroxine (LT4) treatment in women transitioning through midlife. The key takeaways from this longitudinal cohort study include: 1. No statistically significant increase in cardiovascular disease (CVD) events was observed in women treated with LT4 monotherapy compared to those with no thyroid disease. 2. The risk remained comparable even when adjusting for multiple variables and stratifying by thyrotropin (TSH) levels, suggesting that standard clinical management of hypothyroidism is not inherently cardiotoxic in this population. 3. The findings offer significant clinical reassurance to healthcare providers and patients regarding the macrovascular safety of thyroid hormone replacement therapy during the menopause transition.
Introduction: The Intersection of Thyroid Function and Cardiovascular Health
Thyroid hormones play a fundamental role in cardiovascular physiology, influencing heart rate, cardiac output, systemic vascular resistance, and lipid metabolism. Consequently, both overt and subclinical thyroid dysfunctions have long been associated with adverse cardiovascular outcomes. Hypothyroidism is linked to dyslipidemia, diastolic hypertension, and impaired endothelial function, while hyperthyroidism—whether endogenous or iatrogenic—can lead to atrial fibrillation, increased myocardial oxygen demand, and heart failure. For women in midlife, these risks are compounded by the menopause transition, a period characterized by significant shifts in body composition and metabolic health that independently increase cardiovascular risk. Levothyroxine (LT4) monotherapy is the global standard for treating hypothyroidism, yet clinicians often worry about the longitudinal impact of fluctuating hormone levels. This study, derived from the SWAN cohort, addresses whether long-term LT4 treatment translates into a higher incidence of major cardiovascular events.
The Rationale: Why Focus on Levothyroxine and Midlife Women?
The prevalence of hypothyroidism is notably higher in women, particularly as they approach and pass through menopause. While LT4 therapy aims to restore euthyroidism, maintaining a narrow therapeutic window is clinically challenging. Patients often experience periods of over-replacement (leading to subclinical hyperthyroidism) or under-replacement. There has been persistent concern in the medical community that even transient excursions in TSH levels, or the lack of T3 replacement in monotherapy protocols, might contribute to accelerated atherosclerosis or sudden cardiac events over decades of use. Given that cardiovascular disease remains the leading cause of mortality in women, clarifying the relationship between the most common treatment for thyroid disease and long-term heart health is a public health priority.
Study Design: The SWAN Longitudinal Framework
The Study of Women’s Health Across the Nation (SWAN) is a multi-site, multi-ethnic longitudinal study designed to characterize the biological and psychosocial changes occurring during the menopause transition. This specific analysis utilized the robust data gathered from seven geographic sites across the United States, ensuring a diverse and representative cohort.
Defining the Cohort and Exposure
The researchers included 2,647 women in this analysis. At baseline, participants were screened for a history of thyroid disease and the use of LT4. During the follow-up period, which spanned up to 17 visits, thyroid medication use and TSH levels were tracked as time-varying exposures. This approach allowed the researchers to account for changes in treatment status and biochemical control over nearly two decades of follow-up. The control group consisted of women with no history of thyroid disease and no use of thyroid-modifying medications.
Endpoints and Statistical Methodology
The primary endpoint was a composite CVD outcome, encompassing both fatal and nonfatal events. These included myocardial infarction (MI), stroke, heart failure (HF), percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery. To determine the relationship between LT4 treatment and the incidence of the first CVD event, the team employed a multivariable Cox proportional hazards model. This model was adjusted for age, race/ethnicity, body mass index (BMI), smoking status, and other cardiovascular risk factors. Furthermore, a sensitivity analysis was performed to see if TSH levels within the LT4 group (representing the quality of biochemical control) influenced the risk profile.
Detailed Findings: Cardiovascular Outcomes and LT4 Treatment
The results of the SWAN analysis provide a comprehensive look at the safety of thyroid hormone replacement in real-world clinical settings.
Comparative Incidence Rates
Of the 2,647 women studied, 421 (15.9%) received LT4 treatment at some point during the study period. Over the extensive follow-up, 33 CVD events occurred in the LT4-treated group (7.8%), while 191 events occurred in the group without thyroid disease (8.6%). The raw percentage of events was actually slightly lower in the LT4 group, though the difference was not statistically significant (p = 0.616). This initial comparison suggests that treated hypothyroidism does not inherently place a woman at a higher risk than her euthyroid peers.
Hazard Ratios and Sensitivity Analyses
After adjusting for potential confounders in the Cox proportional hazards model, the hazard ratio (HR) for LT4 treatment was 0.85, with a 95% confidence interval of 0.55 to 1.31 (p = 0.463). An HR of 1.0 would signify equal risk; the fact that the interval widely crosses 1.0 indicates no significant association. Crucially, the sensitivity analysis focused on TSH levels found no significant relationship between the degree of biochemical control (as measured by baseline TSH) and subsequent CVD events within the LT4 group. Whether a patient was tightly controlled or had slightly suppressed or elevated TSH at the start of the study, the cardiovascular risk remained stable relative to the control population.
Expert Commentary: Interpreting the Data in Clinical Context
The findings from the SWAN study are significant for several reasons. First, they contrast with some smaller or shorter-term studies that have suggested a potential for increased vascular risk with LT4, particularly when over-replacement occurs. The longitudinal nature of SWAN—following women through the critical menopause transition—adds a layer of robustness that cross-sectional studies lack.
The Role of TSH Monitoring
While the sensitivity analysis did not show a TSH-dependent risk, it is important to note that most women in the SWAN cohort were likely receiving standard clinical care, which involves periodic TSH monitoring and dose adjustments. The lack of excess risk found here may be a testament to the effectiveness of current clinical guidelines in maintaining LT4 therapy within a safe physiological range. It suggests that while individual fluctuations occur, the cumulative exposure to LT4 under standard medical supervision is not a major driver of macrovascular disease.
Iatrogenic Risks and Biological Plausibility
From a mechanistic standpoint, the fear has always been that iatrogenic subclinical hyperthyroidism would increase the risk of arrhythmias or exacerbate underlying coronary artery disease. However, the SWAN data suggests that in the absence of severe, unmonitored thyrotoxicosis, the heart is remarkably resilient to standard LT4 replacement. This may be because LT4 monotherapy provides a steady pool of pro-hormone (T4) that the body converts to the active T3 as needed, potentially buffering the heart from the acute spikes in T3 that might occur with combination therapy or endogenous hyperthyroidism.
Strengths and Limitations of the SWAN Data
The primary strength of this study is its diversity and the length of follow-up. By including women of various ethnicities and following them for 17 visits, the researchers captured the true long-term trajectory of cardiovascular health. However, limitations must be acknowledged. The study focused on LT4 monotherapy; therefore, the results cannot be generalized to patients on T3/T4 combination therapy or desiccated thyroid extract. Additionally, while the composite endpoint was robust, the absolute number of events in the LT4 group (33) may limit the power to detect very small differences in specific sub-types of cardiovascular events, such as heart failure versus stroke.
Conclusion: Reassurance for Clinicians and Patients
The SWAN study concludes that for women transitioning through midlife, the use of levothyroxine for hypothyroidism does not carry an independent excess risk of major cardiovascular events. This is a reassuring finding for the millions of women worldwide who rely on this medication. For clinicians, it reinforces the safety of current LT4 management strategies, provided that standard monitoring is maintained. While the focus of thyroid management should always remain on achieving symptomatic relief and biochemical stability, these data suggest that practitioners do not need to be overly concerned that LT4 replacement itself is contributing to the cardiovascular burden of their aging female patients.
References
1. Ettleson MD, Karavolos K, Burnett-Bowie SM, et al. The Incidence of Cardiovascular Disease Events in Women with Hypothyroidism: The Study of Women’s Health Across the Nation. Thyroid. 2026. doi:10507256261425625.
2. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88(6):2438-2444.
3. El Khoudary SR, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Contemporary Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.
